Current Oncology (Mar 2023)

Consensus Recommendations to Optimize the Detection and Reporting of <i>NTRK</i> Gene Fusions by RNA-Based Next-Generation Sequencing

  • Tracy L. Stockley,
  • Bryan Lo,
  • Adrian Box,
  • Andrea Gomez Corredor,
  • John DeCoteau,
  • Patrice Desmeules,
  • Harriet Feilotter,
  • Daria Grafodatskaya,
  • Cynthia Hawkins,
  • Weei Yuarn Huang,
  • Iyare Izevbaye,
  • Guylaine Lepine,
  • Andreas I. Papadakis,
  • Paul C. Park,
  • Brandon S. Sheffield,
  • Danh Tran-Thanh,
  • Stephen Yip,
  • Ming Sound Tsao

DOI
https://doi.org/10.3390/curroncol30040302
Journal volume & issue
Vol. 30, no. 4
pp. 3989 – 3997

Abstract

Read online

The detection of gene fusions by RNA-based next-generation sequencing (NGS) is an emerging method in clinical genetic laboratories for oncology biomarker testing to direct targeted therapy selections. A recent Canadian study (CANTRK study) comparing the detection of NTRK gene fusions on different NGS assays to determine subjects’ eligibility for tyrosine kinase TRK inhibitor therapy identified the need for recommendations for best practices for laboratory testing to optimize RNA-based NGS gene fusion detection. To develop consensus recommendations, representatives from 17 Canadian genetic laboratories participated in working group discussions and the completion of survey questions about RNA-based NGS. Consensus recommendations are presented for pre-analytic, analytic and reporting aspects of gene fusion detection by RNA-based NGS.

Keywords